HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.

AbstractAIM:
This controlled proof-of-concept study investigated inhaled insulin (INH) as adjunctive therapy to existing oral antidiabetic agents in subjects with type 2 diabetes.
METHODS:
Twenty-four subjects with type 2 diabetes [19 men and 5 women, 56.1 +/- 6.6 years, body mass index 32.7 +/- 4.2 kg/m(2), glycosylated haemoglobin (HbA1c) 8.4 +/- 0.8% (mean +/- s.d.)] inadequately controlled by metformin and/or sulfonylureas were randomized to receive additional therapy with either INH administered preprandially using a metered-dose inhaler (MDI), or insulin glargine (GLA) injected subcutaneously at bedtime for 4 weeks. Both inhaled and injected insulin doses were titrated to predefined blood glucose (BG) targets.
RESULTS:
INH and GLA improved metabolic control to a similar extent. Mean daily BG decreased by 2.8 mmol/l in the INH group (p < 0.001) and by 2.4 mmol/l in the GLA group (p < 0.001). Accordingly, fasting BG (-2.7 vs. -3.6 mmol/l for INH vs. GLA), preprandial- and 2-h postprandial BG, HbA1c (-1.23 vs. -1.05%), body weight (-1.9 vs. -2.3 kg) and serum fructosamine were similarly and significantly reduced in both groups (p < 0.05). Triglycerides decreased significantly with INH (-1.15 micromol/l; p < 0.001) but not with GLA [-0.52 micromol/l; not significant (NS)]. Incidence rates of adverse events did not differ significantly, and there were no indications of respiratory tract irritation.
CONCLUSIONS:
In subjects with type 2 diabetes inadequately controlled by oral agents, preprandial administration of INH delivered by a MDI provided a comparable metabolic control to bedtime GLA and did not show any safety concerns during a 4-week treatment. These results warrant a more extensive investigation of preprandial treatment with INH in longer term studies.
AuthorsM Hausmann, S Dellweg, C Osborn, L Heinemann, A Buchwald, R Rosskamp, P Genova, T Heise
JournalDiabetes, obesity & metabolism (Diabetes Obes Metab) Vol. 8 Issue 5 Pg. 574-80 (Sep 2006) ISSN: 1462-8902 [Print] England
PMID16918593 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Insulin, Long-Acting
  • Sulfonylurea Compounds
  • Insulin Glargine
  • Metformin
Topics
  • Administration, Inhalation
  • Administration, Oral
  • Adolescent
  • Adult
  • Blood Glucose (metabolism)
  • Diabetes Mellitus, Type 2 (blood, drug therapy)
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hypoglycemic Agents (administration & dosage)
  • Injections, Subcutaneous
  • Insulin (administration & dosage, analogs & derivatives, therapeutic use)
  • Insulin Glargine
  • Insulin, Long-Acting
  • Male
  • Metformin (therapeutic use)
  • Middle Aged
  • Pilot Projects
  • Sulfonylurea Compounds (therapeutic use)
  • Treatment Failure

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: